s - only 1 has current (2023) NICE approval - these are:
for pheochromocytomas and paragangliomas
e used in SIRT).
used for GEP-NETs
in the UK for treating unresectable or metastatic, progressive, well- stroenteropancreatic neuroendocrine tumours (NETs) in adults.
indications for usage of 177Lu Radioligand Therapy (to include other ades, e.g., NECs and Grade 3 NETs).
d Alpha Particle Therapy.
Click here to watch the full video about the patient experience of radioligand therapy
Made with FlippingBook - Share PDF online